Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Michele Mayo, Yogesh Chutake, Rahul Karnik, Alice McDonald, Patricia S. Cho, Jessica Filiatrault, Dapeng Chen, Vaishali Dixit, William Proctor, Susanne Breitkopf, Frank Qi, Kan-Nian Hu, Kirti Sharma, Reggie Ewesuedo, Matt Weiss, Joseph D. Growney, Juliet Williams, Stefanie S Schalm

Blood (2022) 140 (Supplement 1): 6239–6240.

https://doi.org/10.1182/blood-2022-169021

Published: 2022

Journal Articles

Runx1 Is Required for Notch-Induced Specification of Megakaryocyte Development from Early Hematopoietic Stem and Progenitor Cells

Melanie G Cornejo, Thomas Mercher, Ph.D, Joseph D. Growney, PhD, Jonathan Jesneck, Ivan Maillard, MD, PhD, Warren S. Pear, MD, PhD, Jon Aster, MD, PhD, D. Gary Gilliland, MD, PhD

Blood (2008) 112 (11): 1370.

https://doi.org/10.1182/blood.V112.11.1370.1370

Published: 2008

Journal Articles

Efficacy of Panobinostat (LBH589) in CTCL Cell Lines and a Murine Xenograft Model: Defining Molecular Pathways of Panobinostat Activity in CTCL.

Wenlin Shao, PhD, Joseph D. Growney, PhD, Yun Feng, MSc, Gregory O’Connor, MSc, Minying Pu, MD, Yung-Mae Yao, PhD, Paul Kwon, BS, Stephen Fawell, PhD, Peter Atadja, PhD

Blood (2007) 110 (11): 1375.

https://doi.org/10.1182/blood.V110.11.1375.1375

Published: 2007

Journal Articles

Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.

Joseph D. Growney, PhD, Peter Atadja, PhD, Wenlin Shao, PhD, Youzhen Wang, PhD, Minying Pu, MD, Brant Firestone, BS, Jane Cheng, MS, Colleen Kowal, BS, Christine Miller, BS, Joseph Eckman, BS, Yung-Mae Yao, PhD, Stephen Fawell, PhD, Andrew Spencer, MD, Jesus F. San Miguel, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 1510.

https://doi.org/10.1182/blood.V110.11.1510.1510

Published: 2007

Journal Articles

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

Jason Gotlib, Caroline Berubé, Joseph D. Growney, Ching-Cheng Chen, Tracy I. George, Christopher Williams, Tomohiro Kajiguchi, Jia Ruan, Stan L. Lilleberg, Jeffrey A. Durocher, Jack H. Lichy, Yanfeng Wang, Pamela S. Cohen, Daniel A. Arber, Michael C. Heinrich, Len Neckers, Stephen J. Galli, D. Gary Gilliland, Steven E. Coutré

Blood (2005) 106 (8): 2865–2870.

https://doi.org/10.1182/blood-2005-04-1568

Published: 2005

Journal Articles

Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype

Joseph D. Growney, Hirokazu Shigematsu, Zhe Li, Benjamin H. Lee, Jennifer Adelsperger, Rebecca Rowan, David P. Curley, Jeffery L. Kutok, Koichi Akashi, Ifor R. Williams, Nancy A. Speck, D. Gary Gilliland

Blood (2005) 106 (2): 494–504.

https://doi.org/10.1182/blood-2004-08-3280

Published: 2005

Journal Articles

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Joseph D. Growney, Jennifer J. Clark, Jennifer Adelsperger, Richard Stone, Doriano Fabbro, James D. Griffin, D. Gary Gilliland

Blood (2005) 106 (2): 721–724.

https://doi.org/10.1182/blood-2004-12-4617

Published: 2005

Journal Articles

PU.1 Is a Critical Downstream Target of AML1.

Gang Huang, PhD, Pu Zhang, MD, Steffen Koschmieder, MD, Joseph D. Growney, PhD, D. Gary Gilliland, MD, Nancy A. Speck, PhD, Daniel G. Tenen, MD

Blood (2004) 104 (11): 358.

https://doi.org/10.1182/blood.V104.11.358.358

Published: 2004

Journal Articles

Loss of Runx1 Perturbs Adult Hematopoiesis and Is Associated with a Myeloproliferative Phenotype.

Joseph D. Growney, PhD, Hirokazu Shigematsu, PhD, Zhe Li, PhD, Benjamin H. Lee, MD, Jennifer Adelsperger, Rebecca Rowan, David P. Curley, Koichi Akashi, MD PhD, Ifor R. Williams, MD PhD, Nancy A. Speck, PhD, D. Gary Gilliland, MD PhD

Blood (2004) 104 (11): 227.

https://doi.org/10.1182/blood.V104.11.227.227

Published: 2004

NARROW

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Runx1 Is Required for Notch-Induced Specification of Megakaryocyte Development from Early Hematopoietic Stem and Progenitor Cells

Efficacy of Panobinostat (LBH589) in CTCL Cell Lines and a Murine Xenograft Model: Defining Molecular Pathways of Panobinostat Activity in CTCL.

Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

PU.1 Is a Critical Downstream Target of AML1.

Loss of Runx1 Perturbs Adult Hematopoiesis and Is Associated with a Myeloproliferative Phenotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only